Profund Advisors LLC Sells 10,150 Shares of Revolution Medicines, Inc. $RVMD

Profund Advisors LLC decreased its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 27.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,929 shares of the company’s stock after selling 10,150 shares during the quarter. Profund Advisors LLC’s holdings in Revolution Medicines were worth $2,145,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Signaturefd LLC lifted its holdings in shares of Revolution Medicines by 33.1% in the fourth quarter. Signaturefd LLC now owns 656 shares of the company’s stock worth $52,000 after acquiring an additional 163 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Revolution Medicines by 57.2% in the fourth quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after acquiring an additional 210 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Revolution Medicines by 44.7% in the fourth quarter. Farther Finance Advisors LLC now owns 751 shares of the company’s stock worth $60,000 after acquiring an additional 232 shares during the last quarter. CWM LLC lifted its holdings in shares of Revolution Medicines by 51.6% in the fourth quarter. CWM LLC now owns 702 shares of the company’s stock worth $56,000 after acquiring an additional 239 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its holdings in shares of Revolution Medicines by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 54,143 shares of the company’s stock worth $2,528,000 after acquiring an additional 336 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on RVMD shares. Piper Sandler increased their target price on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Truist Financial started coverage on shares of Revolution Medicines in a report on Monday. They issued a “buy” rating and a $179.00 target price for the company. Evercore reissued an “outperform” rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a report on Tuesday, April 21st. Finally, Wedbush increased their target price on shares of Revolution Medicines to $165.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Revolution Medicines has an average rating of “Buy” and an average target price of $108.88.

Revolution Medicines Stock Performance

Revolution Medicines stock opened at $147.30 on Wednesday. The business has a 50 day moving average of $120.60 and a 200-day moving average of $99.54. Revolution Medicines, Inc. has a 1 year low of $34.00 and a 1 year high of $155.70. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. The company has a market capitalization of $31.32 billion, a P/E ratio of -20.83 and a beta of 1.41.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the prior year, the business earned ($1.13) earnings per share. On average, equities research analysts predict that Revolution Medicines, Inc. will post -7.75 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Lin Wei sold 2,073 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $206,222.04. Following the completion of the transaction, the insider owned 101,366 shares of the company’s stock, valued at $10,083,889.68. This represents a 2.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Stephen Michael Kelsey sold 4,302 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the completion of the transaction, the insider directly owned 295,398 shares of the company’s stock, valued at $29,386,193.04. This represents a 1.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 184,592 shares of company stock valued at $24,499,532 over the last three months. Insiders own 8.20% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.